The selective serotonin reuptake inhibitor fluoxetine has direct effects on beta cells, promoting insulin secretion and increasing beta-cell mass

Bo Liu | Inmaculada Ruz-Maldonado | Klaudia Toczyska | Oladapo E. Olaniru | Mohammed Gulrez Zariwala | David Hopkins | Min Zhao | Shanta J. Persaud

1Department of Diabetes, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
2Comparative Medicine and Pathology, Vascular Biology and Therapeutics Program (VBT) Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM), Yale University School of Medicine, New Haven, Connecticut, USA
3Centre for Nutraceuticals, School of Life Sciences, University of Westminster, London, UK

Correspondence
Bo Liu and Shanta J. Persaud, Department of Diabetes, School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, UK.
Email: bo.2.liu@kcl.ac.uk; shanta.persaud@kcl.ac.uk

Funding information
Diabetes UK, Grant/Award Number: 14/0005117; UK Medical Research Council, Grant/Award Number: MR/N013700/1

Abstract
Aim: This study investigated whether therapeutically relevant concentrations of fluoxetine, which have been shown to reduce plasma glucose and glycated haemoglobin independent of changes in food intake and body weight, regulate beta-cell function and improve glucose homeostasis.

Methods: Cell viability, insulin secretion, beta-cell proliferation and apoptosis were assessed after exposure of MIN6 beta cells or isolated mouse and human islets to 0.1, 1 or 10 μmol/L fluoxetine. The effect of fluoxetine (10 mg/kg body weight) administration on glucose homeostasis and islet function was also examined in ob/ob mice.

Results: Exposure of MIN6 cells and mouse islets to 0.1 and 1 μmol/L fluoxetine for 72 hours did not compromise cell viability but 10 μmol/L fluoxetine significantly increased Trypan blue uptake. The dose of 1 μmol/L fluoxetine significantly increased beta-cell proliferation and protected islet cells from cytokine-induced apoptosis. In addition, 1 μmol/L fluoxetine induced rapid and reversible potentiation of glucose-stimulated insulin secretion from islets isolated from mice, and from lean and obese human donors. Finally, intraperitoneal administration of fluoxetine to ob/ob mice over 14 days improved glucose tolerance and resulted in significant increases in beta-cell proliferation and enhanced insulin secretory capacity.

Conclusions: These data are consistent with a role for fluoxetine in regulating glucose homeostasis through direct effects on beta cells. Fluoxetine thus demonstrates promise as a preferential antidepressant for patients with concomitant occurrence of depression and diabetes.

1 INTRODUCTION

Fluoxetine, the active pharmaceutical ingredient of the antidepressant Prozac®, is a selective serotonin reuptake inhibitor (SSRI) that is widely believed to mediate its antidepressant effects by enhancing serotonin (5-hydroxytryptamine [5-HT]) neurotransmission. When released, 5-HT is rapidly retrieved following reuptake by the 5-HT transporter, SERT.1 Fluoxetine binds to SERT directly to block the
reuptake of 5-HT from the synaptic cleft, leaving elevated levels of 5-HT available to activate postsynaptic 5-HT receptors and triggering downstream intracellular signalling cascades that reduce the symptoms of depression.\textsuperscript{2–5}

A reciprocal relationship between depression and type 2 diabetes (T2D) has long been reported, with depression being associated with a 60% increase in the risk of developing T2D\textsuperscript{6} and T2D being associated with a 24% increase in the risk of depressive symptoms.\textsuperscript{7} It is not clear whether a common aetiology accounts for the concomitant occurrence of these conditions, but there has been concern regarding increased risk of T2D with long-term use of antidepressants.\textsuperscript{8,9} However, a review of published trials concluded that it is the severe symptoms of depression that these drugs are acting directly on insulin-secreting beta cells to improve insulin secretion and/or expand beta-cell mass.

5-HT is synthesized de novo in beta cells via the rate-limiting enzymes tryptophan hydroxylase 1 and 2 (Tph1 and Tph2)\textsuperscript{15} and aromatic-L-amino acid decarboxylase (AADC),\textsuperscript{16, 17} and it is stored in beta-cell secretory vesicles.\textsuperscript{17} The importance of 5-HT in glycaemic regulation is indicated by the impaired glucose homeostasis observed in mice deficient in peripheral 5-HT.\textsuperscript{18} In addition, 5-HT has been implicated in beta-cell adaptive responses to pregnancy, with reports of enhanced insulin secretion and increased beta-cell mass to compensate for peripheral insulin resistance.\textsuperscript{15, 19–21} It is thus possible that fluoxetine, by increasing local 5-HT levels, has direct effects on the endocrine pancreas. Indeed, there have been earlier studies investigating the effects of SSRIs on beta cells, although these are of limited clinical relevance since fluoxetine was used at concentrations up to 100 μmol/L,\textsuperscript{22–24} which is considerably greater than the steady-state plasma concentrations of 0.3 to 2.6 μmol/L detected in patients with chronic use of fluoxetine.\textsuperscript{25} The aim of this study, therefore, was to determine whether therapeutically relevant concentrations of fluoxetine have the potential to promote insulin release and/or beta-cell expansion, both of which could have therapeutic benefits in diabetes.

2 | MATERIALS AND METHODS

2.1 | Materials

Fluoxetine hydrochloride, collagenase type XI, histopaque-1077, 5-bromo-2'-deoxyuridine (BrdU) and mouse monoclonal anti-BrdU antibody were purchased from Sigma-Aldrich (Poole, UK). Enhanced chemiluminescence (ECL) Western blotting detection reagents, Hyperfilm and Rainbow™ molecular weight markers were obtained from GE Healthcare (Amersham, UK). RNeasy mini kits, RNase-free DNase sets and QuantiTect Primer Assays were from Qiagen (Manchester, UK). The high-capacity cDNA reverse transcription kit was from Thermo Fisher Scientific (Paisley, UK). Anti-SERT antibody was purchased from Abcam (Cambridge, UK). Anti-phospho-ERK, anti-phospho-AKT and anti-phospho-CREB primary antibodies were obtained from Cell Signaling (Hitchin, UK) and the anti-insulin antibody used for immunohistochemistry was from Dako UK Ltd (Ely, UK). AlexaFluor 488- and AlexaFluor 594-conjugated secondary antibodies were obtained from Jackson ImmunoResearch Laboratories (Newmarket, UK). Caspase-Glo 3/7 and CellTiter-Glo assay kits were from Promega (Southampton, UK). Recombinant murine tumour necro-sis factor α (TNFα), interferon γ (IFNγ) and interleukin-1β (IL-1β) were from PeproTech EC (London, UK). PCR was carried out using a Px2 Thermal RT-PCR cycler (Thermo Fisher Scientific, Paisley, UK). Accu-Chek blood glucose meters and strips were from Roche Diagnostics (Burgess Hill, UK). MIN6 beta cells were kindly provided by Junichi I. Miyazaki (University of Osaka, Osaka, Japan).

2.2 | Experimental animals

Male CD-1, C57BL/6 and ob/ob mice (Envigo, Bicester, UK) were maintained at King’s College London, with food and water supplied ad libitum. All animal procedures were approved by the King’s College London Ethics Committee and carried out under licence, in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986.

2.3 | Isolation of mouse and human islets

Islets of Langerhans were isolated from 8-week-old male C57BL/6 mice by collagenase digestion, as described previously.\textsuperscript{26} Human islets of Langerhans were aseptically isolated from pancreases from nondiabetic, heart-beating cadaver organ donors at King’s College Hospital Islet Transplantation Unit with appropriate ethical approval.\textsuperscript{27}

2.4 | Trypan blue uptake

MIN6 beta cells were incubated with 0.1, 1 or 10 μmol/L fluoxetine or vehicle (0.005% v/v DMSO) for 72 hours. The cell membrane integrity of adherent cells was assessed by incubation in a Trypan blue solution (0.1% w/v) for 15 minutes. Cells in the wells were visualized on a Nikon TMS phase contrast microscope and photographs were obtained using a Canon EOS 4000D camera (Tokyo, Japan). In parallel experiments, MIN6 cells were incubated with 0.1, 1 or 10 μmol/L fluoxetine or vehicle (0.005% v/v DMSO) for 72 hours before being trypsinized. Cells to which the dye had gained access (blue) and nonstained cells (white) were then counted on a haemocytometer and percentage viable cells were calculated as percentage of nonstained cells over total number of cells. Viability of isolated mouse islets was assessed similarly except that islet cells were visualized on an Olympus KL300 LED microscope.
2.5 | Cell proliferation

The effect of fluoxetine on MIN6 beta-cell proliferation was quantified using a BrdU ELISA kit, as described previously. For the measurement of beta-cell proliferation in islets, groups of 250 islets from CD-1 mice were incubated with 1 μmol/L fluoxetine or vehicle (0.005% v/v DMSO) in the presence of 1 mg/mL BrdU for 5 days before being fixed and embedded in paraffin. Sections of 5-μm thickness were treated with citrate buffer (10 mmol/L citric acid, 0.05% Tween 20, pH 6.0) and then immunostained with antibodies against BrdU and insulin at 1:100 and 1:200 dilutions, respectively. Immunopositive cells were detected using secondary antibodies conjugated to AlexaFluor 488 (BrdU; green) or AlexaFluor 594 (insulin; red) both at 1:50 dilution. Immunostained sections were visualized using a Nikon Eclipse TE2000-U microscope (Tokyo, Japan), images were acquired with a Nikon Digital Sight-Q1Mc camera (Tokyo, Japan) and analysed using Image J software.

2.6 | Apoptosis

Isolated mouse islets were maintained in culture for 72 hours in the presence of 0.1 or 1 μmol/L fluoxetine, or vehicle (0.005% v/v DMSO). For the last 24 hours of the incubation, a cytokine cocktail (0.025 U/μL IL-1β, 1 U/μL TNFα and 1 U/μL IFNγ) was added to the culture medium. Groups of three islets were then transferred to white-walled 96-well plates and caspase 3/7-induced cleavage of a luminogenic substrate was quantified using a luminometer as described previously.

2.7 | Static insulin secretion

Groups of three mouse and five human islets, randomized in size between treatment groups, were incubated with DMEM containing 2 mmol/L glucose for 1 h before being exposed to 2 mmol/L glucose DMEM or 20 mmol/L glucose DMEM in the absence or presence of 0.1 and 1 μmol/L fluoxetine for another hour. For chronic exposure experiments, isolated mouse or human islets were incubated in DMEM containing 2 or 20 mmol/L glucose in the absence or presence of 0.1 and 1 μmol/L fluoxetine for 72 hours. Islets were then incubated for 1 hour with 2 mmol/L glucose DMEM before being exposed to 2 or 20 mmol/L glucose DMEM for another hour. Insulin secreted into the supernatant was quantified by radioimmunoassay.

2.8 | Dynamic insulin secretion

Groups of 100 randomly selected islets, isolated from C57BL/6, ob/ob mice or lean (body mass index [BMI] 20 kg/m²) and obese (BMI 36 kg/m²) human donors, were transferred to chambers containing 1-μm pore-size nylon filters and perifused at 37°C and a flow rate of 0.5 mL/min in a physiological salt solution, under the conditions described for individual experiments. Samples were collected at 2-minute intervals and secreted insulin was measured by radioimmunoassay.

2.9 | In vivo effects of fluoxetine

Groups of 29-week-old male ob/ob mice were administered four doses of fluoxetine (10 mg/kg body weight delivered in a volume of 0.4 mL DMSO/kg body weight) or vehicle (0.4 mL DMSO/kg body weight) intraperitoneally over 14 days before being subjected to intraperitoneal glucose tolerance tests (ipGTTs) or insulin tolerance tests (ipITTs), during which mice that were fasted overnight (for ipGTTs) or for 6 hours (for ipITTs) received a single intraperitoneal administration of glucose (2 g/kg body weight) or insulin (0.75 U/kg body weight) in the presence of fluoxetine (10 mg/kg body weight) or vehicle (0.4 mL/kg body weight DMSO). Tail vein blood glucose concentrations were determined with an Accu-Chek blood glucose meter. BrdU (1 mg/mL) was delivered to mice in their drinking water for the last 7 days before the mice were killed. Pancreases were dissected from these mice, and BrdU incorporation into beta cells was quantified using immunohistochemistry as described above.

2.10 | Reverse-transcription PCR and quantitative real-time PCR

RNA was extracted from MIN6 beta cells, mouse islets and human islets using RNeasy kits according to the manufacturer’s protocol and reverse-transcribed into cDNAs using a high-capacity cDNA reverse transcription kit. cDNAs were then amplified over 40 cycles using prevalidated primers specific for mouse SERT (Mm_Slc6a4_1_SG QuantiTect Primer Assay QT00163345) and human SERT (Hs_SLC6A4_1_SG QuantiTect Primer Assay QT00058380). For quantification of SERT mRNA expression in islets from lean and obese donors, quantitative real-time PCR was performed in a LightCycler 96 system using QuantiTect Primer Assays and SYBR Green Master I. Primer efficiency for SERT and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 2.02 and 1.98, respectively. Template cDNA from three lean (BMI 21.0 ± 1.5 kg/m²) and three obese (BMI 31.3 ± 0.3 kg/m²) donors were diluted in such a way that all quantified genes returned cycle threshold values <26. Relative expression of SERT mRNA was determined after normalization against GAPDH mRNA expression in the same samples and calculated by the 2^−ΔΔCt method.

2.11 | Single-cell calcium microfluorimetry

Islets isolated from three CD-1 mice were dispersed using cell dissociation solution, and groups of 100 000 islet cells were seeded onto acid ethanol-washed glass coverslips. Cells were maintained in culture overnight, and then loaded with 5 μM Fura-2 AM and perifused
(1 mL/min) on a heated stage with a physiological salt solution containing 20 mmol/L glucose in the presence of 1 μmol/L fluoxetine. Real-time changes in $[\text{Ca}^{2+}]_i$ were determined by illuminating cells alternately at 340 and 380 nm, with the emitted light being filtered at 510 nm, and data were recorded with a charged-coupled device camera every 3 seconds.

**Figure 1** Effects of fluoxetine on beta-cell viability. MIN6 beta cells growing in 96-well plates were exposed to increasing concentrations of fluoxetine for 72 hours and viability of adherent beta cells was assessed by visualization of Trypan blue uptake (A, scale bars: 50 μm). In parallel experiments, MIN6 cells that had been exposed to increasing concentrations of fluoxetine for 72 hours were trypsinized and Trypan blue-stained (blue) and nonstained (white) cells were quantified using a haemocytometer (B, $n = 6$, $**P < 0.0001$ vs. control). For the measurement of islet cell viability, islets isolated from three CD-1 mice were incubated with increasing concentrations of fluoxetine for 72 hours and Trypan blue uptake was assessed by light microscopy (C, scale bars: 100 μm). Trypan blue micrographs are representative of $n = 10$ replicates for MIN6 cells in three independent experiments and $n = 6$ replicates for mouse islets in three independent experiments.
2.12 | Western blotting

For the detection of SERT, 50-μg protein extracts from MIN6 beta cells, human and mouse islets were subjected to polyacrylamide gel electrophoresis and Western blot analysis using an antibody against SERT (1:1000 dilution). For detection of ERK, Akt and CREB phosphorylation in response to fluoxetine, MIN6 beta cells were incubated with 1 μmol/L fluoxetine (delivered in 0.005% vol./vol. DMSO) or vehicle (0.005% vol./vol. DMSO) for 24 hours and parallel groups of cells were also exposed to 10 μmol/L forskolin or 100 nmoL/L insulin for 10 minutes. Cells were then lysed in the presence of phosphatase and protease inhibitors before being probed with antibodies against phospho-ERK (1:1000 dilution), phospho-Akt (1:1000 dilution), phospho-CREB (1:1000 dilution) or beta actin (1:5000 dilution). Immunoreactivity was detected using X-ray film after the addition of ECL substrate. Where necessary, antibodies were removed from polyvinylidene difluoride membranes by incubation with a phosphate-buffered saline solution containing 2-mercaptoethanol (0.7% vol./vol.) and sodium dodecyl sulphate (2% wt./vol.).

2.13 | Statistical analyses

All statistical comparisons were made using Student’s t tests or ANOVA, as appropriate. P values < 0.05 were taken to indicate statistical significance.

3 | RESULTS

3.1 | Therapeutic concentrations of fluoxetine do not compromise beta-cell viability

To examine the role of fluoxetine in regulating beta-cell function, its effect on beta-cell viability at both therapeutically relevant concentrations (0.1 and 1 μmol/L) and at a supra-pharmacological concentration (10 μmol/L) were first measured. Almost all cells exposed to 0.1 and 1 μmol/L fluoxetine excluded entry of Trypan blue and their morphological characteristics were similar to those exposed to vehicle. However, 10 μmol/L fluoxetine caused significant increases in Trypan blue uptake (Figure 1A) and the cells developed a rounded appearance. Quantification of stained and nonstained cells demonstrated that 0.1 and 1 μmol/L fluoxetine did not reduce MIN6 cell viability whereas 10 μmol/L fluoxetine caused a 19.4 ± 2.3% decrease in the percentage of viable cells over the 72-hour incubation period (P < 0.0001 vs. control; Figure 1B). Mouse islets exposed for 72 hours to 0.1 and 1 μmol/L fluoxetine also showed limited Trypan blue uptake while 10 μmol/L fluoxetine caused increased Trypan blue staining, particularly by peripheral cells of the islet apex (Figure 1C). These data indicate that therapeutic concentrations of fluoxetine do not compromise beta-cell viability and fluoxetine was therefore used at 0.1 and 1 μmol/L for further experiments examining its role in regulating beta-cell function.

3.2 | Fluoxetine increases beta-cell proliferation and decreases islet cell apoptosis in vitro

Exposure of MIN6 cells to 0.1 and 1 μmol/L fluoxetine significantly increased BrdU incorporation (Figure 2A; P < 0.05) and this proliferative effect was also observed in isolated mouse islets where 1 μmol/L fluoxetine induced a significant increase in the number of insulin-positive cells expressing BrdU (Figure 2B). Incubation of mouse islets with 0.1 or 1 μmol/L fluoxetine also significantly decreased cytokine-induced islet cell apoptosis (Figure 2C), with the highest reduction in caspase 3/7 activities observed at 1 μmol/L.

3.3 | Fluoxetine potentiates glucose-induced insulin secretion in vitro

Exposure of mouse and human islets to 0.1 and 1 μmol/L fluoxetine, either acutely (Figures 3A,B), or for 72 hours (Figures 3C,D), had no significant effect on basal insulin secretion at 2 mmol/L glucose concentration. Increasing the glucose concentration from 2 to 20 mmol/L significantly stimulated insulin secretion from mouse and human islets, and acute exposure to 1 μmol/L fluoxetine further potentiated glucose-induced insulin secretion (Figure 3A and B). Similar results were observed following pre-incubation of mouse (Figure 3C) and human (Figure 3D) islets to fluoxetine for 72 hours, where significantly increased glucose-induced insulin secretion was observed after chronic exposure to 1 μmol/L fluoxetine.

Similar stimulatory effects of 1 μmol/L fluoxetine were observed in dynamic insulin secretion experiments, in which increasing the glucose concentration from 2 to 20 mmol/L initiated insulin secretory responses from mouse islets (Figure 3E), and from islets isolated from lean (BMI 20 kg/m²; Figure 3F) and obese (BMI 36 kg/m²; Figure 3G) donors. Acute exposure of mouse and human islets to 1 μmol/L fluoxetine led to significant potentiation of glucose-induced insulin secretion that was rapid in onset and reversible upon removal of fluoxetine from the perfusion media (Figures 3E-G, dashed lines).

3.4 | Intermittent intraperitoneal administration of fluoxetine to ob/ob mice improves glucose tolerance in vivo

To examine the role of fluoxetine in regulating beta-cell function in vivo, mice were subjected to two different regimens of daily fluoxetine administration: either 10 mg/kg daily for four days or a single dose of 10 mg/kg fluoxetine on day 1 followed by vehicle on days 2–4. After four days of fluoxetine treatment, plasma glucose levels in fluoxetine-treated mice were significantly lower than those of vehicle-treated mice (Figure 4A). In a second experiment, the same regimen was used but glucose measurements were performed on day 14. Again, mice treated with fluoxetine showed significantly lower plasma glucose levels than vehicle-treated mice (Figure 4B). These results indicate that fluoxetine treatment significantly improves glucose tolerance in vivo.

4 | DISCUSSION

In conclusion, these results demonstrate that fluoxetine is a potential therapeutic agent for the treatment of diabetes mellitus. Further studies are needed to determine the mechanism by which fluoxetine exerts its effects on beta-cell function.
administration, those that had received fluoxetine showed improved glucose clearance (15.2 ± 2.2 mmol/L at t = 210; P < 0.05). As expected, insulin tolerance testing indicated that the control ob/ob mice were overtly insulin-resistant and those that had been pre-exposed to fluoxetine did not show any improvements in insulin sensitivity (Figure 4B), suggesting that the improved glucose handling upon
Fluoxetine administration was a direct result of enhanced beta-cell function and/or mass.

Islets isolated from mice treated with fluoxetine exhibited a more robust insulin secretory response to 20 mmol/L glucose than islets from control mice (Figure 4C). In addition, islet size was increased in mice treated with fluoxetine and there were more beta cells showing incorporation of BrdU (Figure 4D). Quantification of islet area in multiple sections indicated that it was significantly increased after exposure to fluoxetine and this was associated with significantly increased numbers of BrdU and insulin double-positive cells. These data indicate that in vivo chronic delivery of fluoxetine promotes beta-cell proliferation, which, together with direct effects of fluoxetine to potentiate insulin secretion, can overcome the intrinsic insulin resistance of ob/ob mice to marginally improve glucose tolerance.
3.5 Possible mechanisms of actions of fluoxetine in beta cells

Using primers specific for human SERT, an amplicon of 187 bp was obtained when human islet cDNA was used as a template, and a 207-bp product was detected after amplification of mouse islet and MIN6 beta-cell cDNA using primers for mouse SERT (Figure 5A). Additionally, immunoreactive proteins of 70 kDa were detected in Western blots of human and mouse islets, and MIN6 beta cells, using an antibody directed against both human and mouse SERT (Figure 5B). These observations confirm that SERT is expressed by islets and are consistent with fluoxetine acting on
beta cells to inhibit SERT and maintain local endogenous 5-HT levels. Quantification of SERT expression in islets from lean and obese donors indicated that there were no significant differences in the expression levels of SERT mRNA in islets during obesity (Figure 5C).

Since elevations in $[\text{Ca}^{2+}]_i$ are important in the stimulation of insulin secretion, the effects of fluoxetine were evaluated in Fura-2-loaded mouse islet cells using single-cell calcium microfluorimetry. Results from these experiments indicated that, as expected, exposure to 20 mmol/L glucose resulted in a rapid and sustained elevation in $[\text{Ca}^{2+}]_i$, and this was not further enhanced by the addition of 1 μmol/L fluoxetine (Figure 5D). Tolbutamide, the ATP-sensitive K$^+$ channel blocker, stimulated increases in $[\text{Ca}^{2+}]_i$, following exposure to fluoxetine, demonstrating maintenance of the membrane potential and capacity of the beta cells to elevate calcium.

As ERK2, CREB and Akt are known to have pro-proliferative and anti-apoptotic effects in a range of cell types, including beta cells, the ability of fluoxetine to phosphorylate and thus activate these intracellular mediators was examined. It can be seen from Figure 5E that incubation of MIN6 beta cells with 1 μmol/L fluoxetine...
FIGURE 5  Possible mechanisms of actions of fluoxetine in beta cells. Products of PCR using cDNA from human islets, mouse islets and MIN6 beta cells, and species-specific primers for SERT were electrophoretically separated on 1.8% agarose gels. Non-reverse-transcribed RNA was used as a negative control (A). 50 μg protein lysates from human islets, mouse islets and MIN6 beta cells were separated on a 10% polyacrylamide gel and SERT protein expression was detected by Western blot analysis (B). SERT mRNA expression was quantified in islets isolated from lean (body mass index [BMI] 21.0 ± 1.5 kg/m²) and obese (BMI 31.3 ± 0.3 kg/m²) donors and expressed relative to GAPDH mRNA (C). Real-time changes in intracellular calcium in response to exposure to 20 mmol/L glucose, 1 μmol/L fluoxetine and 50 μmol/L tolbutamide were recorded in Fura-2-loaded dispersed mouse islet cells (D, mean ± SEM, n = 50 cells). MIN6 cells were incubated with 1 μmol/L fluoxetine or vehicle (0.005% v/v DMSO) for 24 hours before Western blotting for phosphorylation of ERK (p-ERK), Akt (p-Akt) and CREB (p-CREB) using antibodies against the phosphorylated forms of the corresponding proteins. Levels of protein phosphorylation in response to fluoxetine were compared to those induced by 10-minute exposure of MIN6 beta cells to 10 μmol/L forskolin or 100 nmol/L insulin. Expression of beta actin was used as loading control (E). Data are representative of two (for phospho-Akt) or three (for phospho-ERK and phospho-CREB) different experiments.
resulted in enhanced phosphorylation of ERK2, Akt and CREB. Phosphorylation of these proteins was also stimulated by exposure of MIN6 beta cells to 10 μmol/L forskolin or 100 nmol/L insulin.

4 | DISCUSSION

Fluoxetine (Prozac®) is a safe and effective SSRI that is used as an antidepressant by millions of people worldwide. Several independent studies have indicated beneficial effects of fluoxetine on HbA1c levels\(^{11,14,34,35}\) and the data presented here are consistent with a glucose-lowering effect of fluoxetine that is mediated, at least in part, through promoting beta-cell mass expansion and potentiating glucose-stimulated insulin secretion.

Previous reports of inhibition of insulin secretion from MIN6 beta cells by fluoxetine, resulting from oxidative stress and impaired mitochondrial bioenergetics\(^{22}\) and reduction in endoplasmic reticulum calcium storage,\(^{23}\) are in contrast to our observations of enhanced insulin secretion from both mouse and human islets. These earlier studies used fluoxetine at concentrations of between 10 μmol/L and 100 μmol/L, which are considerably higher than its therapeutically relevant steady-state plasma concentrations of 3 μmol/L.\(^{25,36,37}\)

In vitro fluoxetine use at excessive concentrations may hinder its biofide effects. Indeed, our observations that 10 μmol/L fluoxetine induced cytotoxic effects on beta cells whereas therapeutic fluoxetine concentrations (0.1 and 1 μmol/L) did not compromise beta-cell viability support this notion and prompted us to re-evaluate the direct effects of therapeutically relevant concentrations of fluoxetine on beta-cell function and mass.

We have demonstrated here, for the first time, that when used at the therapeutically relevant concentration of 1 μmol/L, fluoxetine potentiated glucose-induced insulin secretion from mouse and human islets in vitro, indicating its direct stimulatory effect on the endocrine pancreas. We used islets from obese as well as lean donors as there is evidence that a large proportion of people taking SSRIs are overweight or obese.\(^{38-40}\) Our data indicated that 1 μmol/L fluoxetine did potentiate glucose-induced insulin secretion from islets obtained from the obese donor, suggesting that obese individuals taking this SSRI would benefit from its direct effects to enhance insulin secretion and the lack of effect of fluoxetine on basal insulin secretion at 2 mmol/L glucose suggests that it is unlikely to induce hypoglycaemia in the fasting state. We also found that 0.1 and 1 μmol/L fluoxetine promoted beta-cell proliferation and protected islet cells from cytokine-induced apoptosis. These in vitro observations are consistent with the improved glucose tolerance induced by fluoxetine administration to ob/ob mice, a leptin-deficient model of obesity and hyperglycaemia. The improved glycaemic control was not associated with any reduction in insulin resistance in this model, suggesting that the primary site of action of fluoxetine was the beta cells. Consistent with this, islets isolated from fluoxetine-treated mice demonstrated increased capacity to secrete insulin in response to 20 mmol/L glucose. Furthermore, measurement of BrdU incorporation into islet cells from the fluoxetine-treated mice showed significantly elevated levels of beta-cell proliferation. Taken together, it is possible that the increased insulin secretory capacity and augmented beta-cell mass account for the improvement in glucose tolerance seen in ob/ob mice chronically administered fluoxetine. Nonetheless, the overt insulin resistance of these mice most likely accounted for the delayed reduction in glucose levels observed in the ipGTTs, and use of milder mouse models of glucose dysregulation may allow the in vivo glucose-lowering effect of fluoxetine to be more readily seen. The dose and duration of fluoxetine used in the in vivo experiments are in line with previously published studies where fluoxetine has been delivered in vivo\(^{41-43}\) and plasma concentrations of fluoxetine remain in the low micromolar range even upon chronic use at 10 mg/kg/d.\(^{44,45}\)

We detected SERT mRNA and protein in MIN6 beta cells and in mouse and human islets, and exposure of human islets to another SSRI, fluvoxamine, significantly increased the level of extracellular 5-HT.\(^{46}\) Although it has been reported that SERT availability is decreased in brain regions in obesity,\(^{37}\) we found that islet expression of SERT mRNA was not changed significantly during obesity, when there is an increased metabolic demand for insulin. Our observations provide initial evidence that fluoxetine inhibition of beta-cell SERT may maintain local levels of endogenous 5-HT in the islet extracellular space, allowing it to stimulate insulin secretion.\(^{15,19,20,48,49}\) These 5-HT-dependent effects may be mediated through specific members of the 5-HT receptor superfamily. Islets express several 5-HT receptors, among them both the G\(_{q}\)-coupled 5-HT\(_2\) and the G\(_{s}\)-coupled 5-HT\(_4\) have been shown to promote insulin exocytosis.\(^{48,49}\) However, we did not observe increases in [Ca\(_{\text{2+}}\)], when mouse islet cells were exposed to fluoxetine, suggesting that its ability to potentiate insulin secretion is independent of [Ca\(_{\text{2+}}\)] influx or mobilization and therefore G\(_{q}\)-coupled 5-HT\(_2\) signalling is unlikely to be important in its effects to stimulate insulin secretion. The 5-HT-dependent effects of fluoxetine could be mediated through mechanisms other than activation of 5-HT receptors. For example, it has been proposed that 5-HT may be covalently coupled to the small GTPases Rab3a and R2b27a in a process termed serotonylation, and this can lead to increased insulin secretion.\(^{18}\)

There are several mechanisms through which fluoxetine could promote beta-cell mass expansion. Thus, increased local 5-HT after exposure of islets to fluoxetine could play a role in driving beta-cell proliferation\(^{15,19-21}\) and this is consistent with fluoxetine-induced proliferation of cells in the central nervous system being mediated through 5-HT-dependent modulation of 5-HT\(_1\) and/or 5-HT\(_2\).\(^{50}\) Activation of the transcription factor nuclear factor κB (NFκB) by proinflammatory cytokines such as IL-1β and TNFα promotes beta-cell apoptosis\(^{51,52}\) and fluoxetine has previously been reported to inhibit NFκB signalling in other cell types.\(^{53}\) so it is possible that reduction in NF-kB expression or activity may be involved in fluoxetine-mediated protection of cytokine-induced beta-cell apoptosis. The increased insulin secretion in response to fluoxetine could also be responsible for its proliferative and anti-apoptotic effects since insulin itself has an autocrine effect to promote beta-cell proliferation and reduce beta-cell apoptosis.\(^{54}\) Alternatively, the increase in beta-cell proliferation could be a consequence of increased phosphorylation of the transcription factor CREB, which can be induced directly by fluoxetine, or through 5-HT-dependent or -independent activation of CaMK4.
and/or ERK2 (p42 MAPK) phosphorylation. We, and others, have identified that ERK2 plays important roles in regulating beta-cell proliferation and we have previously demonstrated that CaMK4-mediated CREB phosphorylation regulates Irs2 expression, and subsequently beta-cell proliferation and apoptosis. Consistent with this, we found that 1 μmol/L fluoxetine increased phosphorylation of ERK2 and CREB in MIN6 beta cells. Fluoxetine also stimulated Akt phosphorylation, as it is reported to do in neural stem cells, and this may contribute to its protection against cytokine-induced apoptosis.

In summary, data presented in this study are consistent with a direct role for fluoxetine in promoting beta-cell secretory capacity and maintaining functional beta-cell mass. These effects could contribute to the established satiety-inducing effects of elevated 5-HT to mediate the improved glucose homeostasis observed in fluoxetine-treated patients with depression and T2D. Results presented here may pave the way for fluoxetine to be recommended as a preferential antidepressant for patients with concomitant occurrence of depression and diabetes.

**REFERENCES**

1. Rudnick G. Structure/function relationships in serotonin transporter: new insights from the structure of a bacterial transporter. *Handb Exp Pharmacol*. 2006;175:79-93.
2. Fuller RW, Perry KW, Molloy BB. Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140). *Life Sci*. 1974;16(6):1161-1171.
3. Wong DT, Bymaster FP, Horng JS, Molloy BB. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. *J Pharmacol Exp Ther*. 1975;193(3):804-811.
4. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. *Eur J Pharmacol*. 1997;340(2-3):249-258.
5. Nakkenhoff AG, Moussa-Touks AB, McMeekin AM, Veenstra-VanderWeele J, Blakely RD. Essential contributions of serotonin transporter inhibition to the acute and chronic actions of fluoxetine and citalopram in the SERT Met172 mouse. *Neuropsychopharmacology*. 2016;41(7):1733-1741.
6. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. *Diabetes Care*. 2008;31(12):2383-2390.

7. Nouwen A, Winkley K, Twisk J, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. *Diabetologia*. 2010;53(12):2480-2486.
8. Salvi V, Grua I, Cerveri G, Menacci C, Barone-Adesi F. The risk of new-onset diabetes in antidepressant users - a systematic review and meta-analysis. *PLoS One*. 2017;12(7):e0182088.
9. Kivimäki M, Batty GD, Jokela M, et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? *Biol Psychiatry*. 2011;70(10):978-984.
10. Deuschle M. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. *Curr Opin Psychiatry*. 2013;26(1):60-65.
11. Ye Z, Chen L, Yang Z, et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. *PLoS One*. 2011;6(7):e21511.
12. Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dastih-Khavidaki S. Comparing the effects of 8-week treatment with fluoxetine and fluvoxamine on fasting blood glucose of patients with major depressive disorder. *J Clin Psychopharmacol*. 2004;24(4):386-388.
13. Biagetti B, Corcoy R. Hypoglycemia associated with fluoxetine treatment in a patient with type 1 diabetes. *World J Clin Cases*. 2013;1(5):169-171.
14. Thamaraj A, Stahl D, Hopkins CWP, et al. The association between selective serotonin reuptake inhibitors and Glicemica: a systematic review and meta-analysis of randomized controlled trials. *Psychosom Med*. 2019;81(7):570-583.
15. Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. *Nat Med*. 2010;16(7):804-808.
16. Ahnén B, Wierup N, Sundler F. Neuropeptides and the regulation of islet function. *Diabetes*. 2006;55( Supplement 2):S98-S107.
17. Cataldo Bascunan LR, Lyons C, Bennett H, Artner I, Fex M. Serotonergic regulation of insulin secretion. *Acta Physiol (Oxf)*. 2019;225(1):e13101.
18. Paulmann N, Grohmann M, Voigt JP, et al. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotononinylation. *PLoS Biol*. 2009;7(10):e1000229.
19. Ohara-Imaizumi M, Kim H, Yoshida M, et al. Serotonin regulates glucose-stimulated insulin secretion from pancreatic beta cells during pregnancy. *Proc Natl Acad Sci U S A*. 2013;110(48):19420-19425.
20. Goyvaerts L, Schraenen A, Schaft F. Serotonin competence of mouse beta cells during pregnancy. *Diabetologia*. 2016;59(7):1356-1362.
21. Schraenen A, Lemaire K, de Faudeur G, et al. Placental lactogens induce serotonin biosynthesis in a subset of mouse beta cells during pregnancy. *Diabetologia*. 2010;53(12):2589-2599.
22. Elmorsy E, Al-Ghafari A, Heily ANM, Hissab AS, Oehre B, Smith PA. Editor’s highlight: therapeutic concentrations of antidepressants inhibit pancreatic Beta-cell function via mitochondrial complex inhibition. *Toxicol Sci*. 2017;158(2):286-301.
23. Chang H-Y, Chen S-L, Shen M-R, Kung M-L, Chuang L-M, Chen Y-W. Selective serotonin reuptake inhibitor, fluoxetine, impairs E-cadherin-mediated cell adhesion and alters calcium homeostasis in pancreatic beta cells. *Sci Rep*. 2017;7(1):3515.
24. Issac R, Boura-Halfon S, Gurevitch D, Shainskaya A, Levkovitz Y, Zick Y. Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic beta cells. *J Biol Chem*. 2013;288(8):5682-5693.
25. Bolo NR, Hodé Y, Nédélec J-F, Lainé E, Wagner G, Macher J-P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. *Neuropsychopharmacology*. 2000;23(4):428-438.
26. Atanes P, Ruz-Maldonado I, Olanurin OE, Persaud SJ. Assessing mouse islet function. *Methods Mol Biol*. 2020;2128:241-268.
27. Huang G, Zhao M, Jones P, et al. The development of new density gradient media for purifying human islets and islet-quality assessments. *Transplantation*. 2004;77(1):143-145.
28. Liu B, Barbosa-Sampaio H, Jones PM, Persaud SJ, Muller DS. The CaMK4/CREB/IRS-2 Cascade stimulates proliferation and inhibits apoptosis of β-cells. PLoS One. 2012;7(9):e45711.

29. Ruz-Maldonado I, Liu B, Atanes P, et al. The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling. Cell Mol Life Sci. 2020;77:4709-4723.

30. Gey GO, Gey MK. The maintenance of human Normal cells and tumor cells in continuous culture: I. Preliminary report: Cultivation of mesoblastic tumors and normal tissue and notes on methods of cultivation. Am J Cancer. 1936;27(1):43-76.

31. Jiang WJ, Peng YC, Yang KM. Cellular signaling pathways regulating β-cell proliferation as a promising therapeutic target in the treatment of diabetes (review). Exp Ther Med. 2018;16(4):3275-3285.

32. Hoarau E, Chandra V, Rustin P, Scharffmann R, Duvillie B. Pro-oxidant/antioxidant balance controls pancreatic β-cell differentiation through the ERK1/2 pathway. Cell Death Dis. 2014;5(10):e1487.

33. Kim TK, Lee JS, Jung HS, et al. Triiodothyronine induces proliferation of pancreatic β-cells through the MAPK/ERK pathway. Exp Clin Endocrinol Diabetes. 2014;122(4):240-245.

34. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med. 1995;12(5):416-418.

35. O’Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med. 1994;11(1):105-110.

36. Ville SM, Cooreman SG, Neels HM, Lambert WE. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci. 2008;45(1):25-89.

37. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol. 1996;78(4):203-208.

38. Chávez-Castillo M, Ortega J, Fernández-Nogales A. The non-canonical NF-κB pathway is induced by cytokines in pancreatic beta cells and contributes to cell death and proinflammatory responses in vitro. Diabetologia. 2016;59(3):512-521.

39. Sawyer EK, Howell LL. Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration. Pharmacology. 2011;88(1-2):44-49.

40. Dukulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology. 2004;29(7):1321-1330.

41. Almaka J, Molina J, Menegaz D, et al. Human Beta cells produce and release serotonin to inhibit glucagon secretion from alpha cells. Cell Rep. 2016;17(12):3281-3291.

42. van Galen KA, Booij J, Schrantee A, et al. The response to prolonged fasting in hypothalamic serotonin transporter availability is blunted in obesity. Metabolism. 2021;123:154839.

43. Bennet H, Mollet IG, Balhuizen A, et al. Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans. Diabetologia. 2016;59(4):744-754.

44. Chen H, Hong F, Chen Y, et al. Activation of islet 5-HT4 receptor regulates glycemic control through promoting insulin secretion. Eur J Pharmacol. 2016;789:354-361.

45. Banas M, Hery M, Printemps R, Duszata A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology. 2004;29(3):450-460.

46. Meyerovich K, Fukaya M, Terra LF, Ortis F, Eizirik DL, Cardozo AK. The non-canonical NF-κB pathway is induced by cytokines in pancreatic beta cells and contributes to cell death and proinflammatory responses in vitro. Diabetologia. 2016;59(3):512-521.

47. Song T, Liu H, Tian Z, Xu C, Liu J, Guo Y. Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells. Onco Targets Ther. 2015;8:2199-2208.

48. Muller D, Huang GC, Amiel S, Jones PM, Persaud SJ. Identification of insulin signaling elements in human beta-cells: autocrine regulation of insulin gene expression. Diabetes. 2006;55(10):2835-2842.

49. Zhang S, Li B, Lovatt D, et al. 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional ‘serotonin-specific reuptake inhibitors’. Neuron Glia Biol. 2010;6(2):113-125.

50. Song N, Nakagawa S, Izumi T, et al. Involvement of CaMKIV in neurogenic effect with chronic fluoxetine treatment. Int J Neuropsychopharmacol. 2013;16(4):803-812.

51. Qi X, Lin W, Li J, et al. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis. 2008;31(2):278-285.

52. Burns CJ, Squires PE, Persaud SJ. Signaling through the p38 and p42/44 mitogen-activated families of protein kinases in pancreatic beta-cell proliferation. Biochem Biophys Res Commun. 2000;268(2):544-546.

53. Persaud SJ, Liu B, Sampaio HB, Jones PM, Muller DS. Calcium/calmodulin-dependent kinase IV controls glucose-induced Irs2 expression in mouse beta cells via activation of cAMP response element-binding protein. Diabetologia. 2011;54(5):1109-1120.

54. Wang W, Zhao Y, Zhu X, et al. Fluoxetine upregulates phosphorylated-AKT and phosphorylated-ERK1/2 proteins in neural stem cells: evidence for a crosstalk between AKT and ERK1/2 pathways. J Mol Neurosci. 2013;49(2):244-249.

55. Meng Y, Wang W, Kang J, Wang X, Sun L. Role of the PI3K/AKT signalling pathway in apoptotic cell death in the cerebral cortex of streptozotocin-induced diabetic rats. Exp Ther Med. 2017;13(5):2417-2422.